- Home
- LGMK vs CYCC Comparison
LGMK vs CYCC Comparison
Compare LGMK & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGMK
- CYCC
- Stock Information
- Founded
- LGMK 2011
- CYCC 1992
- Country
- LGMK United States
- CYCC United States
- Employees
- LGMK N/A
- CYCC N/A
- Industry
- LGMK Industrial Specialties
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- LGMK Health Care
- CYCC Health Care
- Exchange
- LGMK Nasdaq
- CYCC Nasdaq
- Market Cap
- LGMK 1.6M
- CYCC 1.8M
- IPO Year
- LGMK N/A
- CYCC N/A
- Fundamental
- Price
- LGMK $0.10
- CYCC $0.37
- Analyst Decision
- LGMK
- CYCC Buy
- Analyst Count
- LGMK 0
- CYCC 2
- Target Price
- LGMK N/A
- CYCC $11.00
- AVG Volume (30 Days)
- LGMK 59.1M
- CYCC 3.7M
- Earning Date
- LGMK 11-12-2024
- CYCC 11-12-2024
- Dividend Yield
- LGMK N/A
- CYCC N/A
- EPS Growth
- LGMK N/A
- CYCC N/A
- EPS
- LGMK N/A
- CYCC N/A
- Revenue
- LGMK $10,078,502.00
- CYCC $74,000.00
- Revenue This Year
- LGMK N/A
- CYCC N/A
- Revenue Next Year
- LGMK N/A
- CYCC $16.28
- P/E Ratio
- LGMK N/A
- CYCC N/A
- Revenue Growth
- LGMK 4.44
- CYCC N/A
- 52 Week Low
- LGMK $0.07
- CYCC $0.35
- 52 Week High
- LGMK $2.20
- CYCC $6.00
- Technical
- Relative Strength Index (RSI)
- LGMK 43.72
- CYCC 29.98
- Support Level
- LGMK $0.07
- CYCC $0.35
- Resistance Level
- LGMK $0.16
- CYCC $0.52
- Average True Range (ATR)
- LGMK 0.03
- CYCC 0.07
- MACD
- LGMK 0.00
- CYCC -0.01
- Stochastic Oscillator
- LGMK 10.34
- CYCC 3.94
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.